Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Vectorious Medical Technologies closes $5 million financing round

Vectorious Medical Technologies, an Israeli company developing a novel cardiac monitoring system for patients suffering from congestive heart failure (CHF), announced today that it has closed a $5 million financing round.

26 Feb 2015

Novartis’ heart failure medicine LCZ696 granted FDA priority review

LCZ696, a twice-a-day medicine being investigated for heart failure, acts to enhance the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).

16 Feb 2015

Young women report greater stress than men after heart attack

Young and middle-aged women experience more stress than their male counterparts, which could contribute to worse recovery from acute myocardial infarction (AMI), according to new findings by Yale School of Medicine researchers and their colleagues.

15 Feb 2015

OSTAR introduces Cellular TeleHealth Blood Pressure Monitoring System in North America

OSTAR Healthcare Technology, a Washington State Based TeleHealth Solutions company, announced the North American launch of yet another first in their Cellular TeleHealth Blood Pressure Monitoring System.

30 Jan 2015

Study finds no evidence that testosterone replacement therapy increases cardiovascular risk

Fears of a link between testosterone replacement therapy and cardiovascular risk are misplaced, according to a review published in this month's Mayo Clinic Proceedings. The therapy has come under widespread scrutiny in recent months, including by a federal Food and Drug Administration panel convened last fall.

28 Jan 2015

Current flu vaccine still offers protection, says Loyola infectious disease specialist

In baseball, three strikes and you're out. The most common annual vaccine targets three strains of flu virus. This year, two vaccine strains are spot on and successfully matched. One strain is partially mismatched, but still believed to offer partial coverage for that strain. The current flu vaccine is still in the game and, more importantly, keeping people well and on the playing field, says a Loyola University Medical Center infectious disease specialist.

8 Jan 2015

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.

30 Dec 2014

C3BS enrols 240th patient in CHART-1 European trial of C-Cure for treatment of congestive heart failure

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the enrolment of the 240th patient in its CHART-1 European trial for C-Cure, the first and only stem cell therapeutic using guided stem cells for the treatment of congestive heart failure.

19 Dec 2014

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta Pharmaceuticals LLC, today announced that the Journal of Clinical Rheumatology published a comprehensive review of a post-hoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized Phase III trials and one open-label extension trial.

14 Dec 2014

Carboplatin and paclitaxel show promise for advanced thymic carcinoma

A multicentre, phase II study of carboplatin and paclitaxel in chemotherapy-naïve patients with advanced thymic carcinoma has shown that the treatment has promising efficacy compared with standard anthracycline-based chemotherapy.

10 Dec 2014

Study evaluates effect of 2011 ACGME duty hour reforms on patient outcomes

In the first year after the Accreditation Council for Graduate Medical Education (ACGME) reduced the number of continuous hours that residents can work, there was no change in the rate of death or readmission among hospitalized Medicare patients, according to a new study published in JAMA.

10 Dec 2014

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation.

24 Nov 2014

Findings illustrate need to monitor all races of heart failure patients for atrial fibrillation

Black patients who have been diagnosed with heart failure are no less likely than white patients to get atrial fibrillation (an irregular heartbeat, or arrhythmia), according to a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania, which was presented today at the 2014 Scientific Sessions of the American Heart Association.

18 Nov 2014

New algorithm could help determine how to treat patients having difficulty breathing

Paramedics respond to a 911 call to find an elderly patient who's having difficulty breathing. Anxious and disoriented, the patient has trouble remembering all the medications he's taking, and with his shortness of breath, speaking is difficult. Is he suffering from acute emphysema or heart failure? The symptoms look the same, but initiating the wrong treatment regimen will increase the patient's risk of severe complications.

7 Nov 2014

Study: Certain prostate cancer medications linked to cardiac death risk

A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, the findings will help doctors and patients weigh the benefits and risks of the drugs.

30 Oct 2014

ASI treats first patient using Peregrine System Infusion Catheter

Ablative Solutions, Inc., a privately held company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has treated the first patient in the Peregrine Study.

14 Oct 2014

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure in Switzerland.

14 Oct 2014

Allscripts FollowMyHealth Achieve now available for patient engagement innovation

Allscripts has announced the market launch and general availability of Allscripts FollowMyHealth Achieve, a consumer-friendly, patient engagement innovation intended to mobilize and empower patients as active partners in the management of their care.

9 Oct 2014

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015.

7 Oct 2014

Occlutech's Paravalvular Leak Closure Device European CE Mark approval

Occlutech, a leading innovator of products to treat structural heart disease today announced that it has obtained a European CE Mark approval for its dedicated Paravalvular Leak Closure Device, (PLD).

29 Sep 2014